• Bulletin of the Korean Chemical Society
• /
• 제30권11호
• /
• pp.2626-2630
• /
• 2009

2'($\beta$)-Hydroxymethylated adenosine is a potent and selective inhibitor of hepatitis C virus (HCV) replication. It targets the RNA-dependent RNA polymerase of HCV, NS5B. Synthesis and antiviral evaluation of carbocyclic versions are described. The cyclopentene intermediate ($9\beta$) was successfully synthesized through sequential Johnson-Claisen orthoester rearrangement and ring-closing metathesis (RCM). Coupling of bases via a Pd(0) catalyst, selective dihydroxylation, and desilylation yielded the target nucleoside analogues. The compounds 17 and 18 were assayed for their ability to inhibit HCV RNA replication in a subgenomic replicon Huh7 cell line and showed moderate antiviral activity with toxicity up to 20.0 and 24.7 ${\mu}g/mL$, respectively.

• 생약학회지
• /
• 제23권2호
• /
• pp.81-88
• /
• 1992

The effects of scoparone, one of coumarin derivative on the hepatic bromobenzene metabolizing enzyme system was estimated in rats. Scoparone pretreatment revealed dose-dependently the recovery of decrease in epoxide hydrolase activity due to the bromobenzene(310 mg/kg, i.p.) treatment. And also scoparone and scopoletin (each 5mg/kg, p.o.) pretreatments showed two times increase in the $V_{max}$ values compared to those of bromobenzene-treated group which were calculated from tripartite reciprocal plots. The mode of protective effect of scoparone against bromobenzene induced toxicity is considered to be due to the induction of microsomal enzyme activity by scopoletin, the intermediate metabolite of scoparone. The changes in cytochrome P-450 activity, aminopyrine N-demethylation, aniline hydroxylation and glutathione S-transferation in scoparone-treated group were not significantly different from those of the control group.

• Toxicological Research
• /
• 제23권4호
• /
• pp.391-403
• /
• 2007

The study was conducted to assess the repeated dose and reproduction and developmental toxicities of acetanilide, an intermediate for drug production, as a part of OECD Screening Information Data Set (SIDS) program. The test agent was administered by gavage at dose levels of 0, 22, 67, 200 and 600 mg/kg to Sprague-Dawley rats (12/group/sex) during pre-mating and mating period for males(up to 30 days) and females and pregnancy and early lactation period for females (up to 39-50 days). At 22 mg/kg, decreases in HGB, HCT (males) and MCHC (females), hyperplasia of spleen red pulp, hyperplasia of femur bone marrow (both sexes) were observed. At 67 mg/kg, salivation (males), reduced food consumption (both sexes), decreases in RBC, HGB, HCT and MCHC (males), increases in MCV (males) and spleen weight (males), hyperplasia of spleen red pulp and femur bone marrow (both sexes) were observed. At 200 mg/kg, decreases in locomotor activity and salivation (both sexes), reduced food consumption (both sexes), decreases in RBC, HGB, HCT and increases in MCV, MCH, BUN, T-BIL (males), enlargement of spleen (both sexes), increased weight of spleen (males), hyperplasia of spleen red pulp and femur bone marrow and extramedullary hematopoiesis of liver (both sexes), atrophy of thymus and corpus luteum hyperplasia of ovary (females) were observed. At 600 mg/kg, decreases in locomotor activity, cyanosis (both sexes), reddish tear, and salivation (males), mortality (4 out of 12 females), decreased body weight (females), reduced food consumption (both sexes), decreases in RBC, HGB, HCT and MCHC and increases in WBC, MCV, MCH, reticulocyte, neutrophil, lymphocyte, monocyte, AST, ALT, BUN, T-BIL, ALB, Ca and A/G ratio (males), enlargement of spleen, increased weights of spleen (both sexes), liver (males), kidney and ovary, decreased weights of thymus (females), hyperplasia of spleen red pulp, hyperplasia of femur bone marrow and extramedullary hematopoiesis of liver (both sexes), and atrophy of thymus and corpus luteum hyperplasia of ovary (females) were observed. Regarding the reproduction and development toxicities, there were no treatment-related changes in precoital time, mating index, fertility index and pregnancy index at all doses tested. At 22 and 67 mg/kg, there were no adverse effects on all the parameters observed. At 200 mg/ kg, decreased body weight of pups (day 4 p.p.) were observed. At 600 mg/kg, decreased body weight of pups (day 0 and 4 p.p.) and viability index (day 4 p.p.), increased incidence of newborns dead or with abnormal clinical signs were observed. The results suggest that the NOAELs for general toxicity are < 22 mg/kg, LOAELs are 22 mg/kg and the NOAELs for reproductive toxicity are 67 mg/kg.

• 대한약리학회지
• /
• 제26권2호
• /
• pp.185-192
• /
• 1990

Diallyl disulfide의 간손상 예방효과를 검토할 목적으로 mouse에 bromobenzene을 투여해 간 손상의 model을 만든 다음 실험을 행하였을 때, diallyl disulfide를 전처치한 실험군이 대조군에 비하여 간손상의 정도가 경미하게 나타났다. 한편 diallyl disulfide의 간손상예방 효과 기전을 구명할 목적으로 bromobenzene의 활성화 및 해독 관련 효소들의 활성을 검토하였을때 활성화 효소인 aniline hydroxylase와 해독 효소의 일종인 epoxide hydrolase의 활성은 diallyl disulfide 전처치에 의해 변동이 없었으나, 나머지 해독 효소인 glutathione S-transferase의 활성은 유의 하게 증가되었고 이의 포합인자인 glutathione의 함량도 증가하였다. 또한 diallyl disulflde에 의한 glutathione S-transferase 활성 증가현상이 어떠한 기전으로 나타나는지 검토 하였을때, diallyl disulfide를 전처치 함으로서 Km치는 별다른 차이가 없었으나 Vmax치는 대단히 증가하였다. 그러나 시험관내에서 diallyl disulfide의 첨가농도를 증가시켰을 때에는 효소활성은 변하지 않았다. 이러한 실험결과들을 종합해 볼 때, diallyl disulfide 전처치에 의한 bromobenzene이 유도한 간손상의 예방효과는 diallyl disulfide가 bromobenzene의 독성 중간 대사산물인 bromobenzene 3,4-oxide를 해독하는 glutathione S-transferase 단백의 합성을 유도함으로서 나타난 결과로 사료되어지나 이점에 대해서는 추후 계속적인 연구 검토가 행해져야 할것이다.

• Toxicological Research
• /
• 제6권2호
• /
• pp.167-182
• /
• 1990

Dietary restriction (caloric restriction) is the only intervention which has been reliably shown to extend the maximum life span of warm-blooded animals and delay the many phenomena associated with aging. It is also one of the most effective modulators of toxicity, especially cancer endpoints. In spite of the known modulator effects of caloric restriction, the biological mechanisms responsible for these effects had not been in vestigated until recently. The National Center for Toxicological Research (NCTR), in a collaborative effort with the National Institute of Aging (NIA), initiated a project whereby nine (9) combinations of rodent species/strains and diets were fed both restricted and ad libitum. The NIA's initiative was to identify biomarkers of aging whereas NCTR's initiative was to identify the biological effects associated with the profound effects caloric restriction has in protecting against both spontaneous (age-related) and chemically-induced toxic endpoints. Independent of sex or species, caloric restriction has similar effects on body temperature, oxygen consumption and $CO_2$production. Caloric restriction also decreased lipid glycolysis and metabolism in rats and mice, which suggest decreased production of metabolites which could lead to fatty acid epoxide formation. The age-associated loss of ciradian regulation of intermediate enzymes is also significantly reduced. Moreover, caloric restriction reduced the age-associated feminization of sexually dimorphic liver isozymes, increased several glucocorticoid responsive isozymes, elevated glucagon/insulin ratios, produced less microsomal superoxide and enhanced the capacity for utilzing detoxicating metabolic pathways. Calorically restricted rats have less than half the number of aflatoxin ($AFB_1$)-DNA adducts than ad libitum animals and urinary excretion of $AFB_1$ was increased significantly. Finally, DNA repair mechanisms are enhanced and oncogene expression is decreased in calorically restricted animals.

• Biomolecules & Therapeutics
• /
• 제14권4호
• /
• pp.240-245
• /
• 2006

The primary use for glycidol is as a stabilizer in the manufacture of vinylpolymers, however, it is also used as an intermediate in the production of pharmaceuticals, as an additives for oil and synthetic hydraulic fluids, and as a diluting agent is same epoxy resins. In this study, we have carried out in vitro genetic toxicity test of glycidol and microarray analysis of differentially expressed genes in response to glycidol. The result of Ames test showed mutations with glycidol treatment in base substitution strain TA1535 both with and without exogenous metabolic activation. Likewise, glycidol showed mutations in frame shift TA98 both with and without exogenous metabolic activation. The result of COMET assay in L5178Y cells with glycidol treatment showed DNA damage both with and without exogenous metabolic activation. Glycidol increased micronuclei in CHO cells both with and without exogenous metabolic activation. 150 Genes were selected as differentially expressed genes in response to glycidol by microarray analysis and these genes would be candidate biomarkers of genetic toxic action of glycidol.

• Environmental Analysis Health and Toxicology
• /
• 제15권1_2호
• /
• pp.19-29
• /
• 2000

아세트아닐리드는 의약품과 염료의 합성과정에서 중간체로서 공기와 폐수를 통하여 환경 중에 방출될 수 있다. 아세트아닐리드는 호기적 조건하에서 신속히 생분해되고 OH 래디컬의 존재하에 간접적으로 광분해된다. 생물농축계수는 4.5로 추정되므로 수생생물에서의 생물농축은 낮을 것으로 예상된다. 아세트아닐리드에 관한 생태독성학적 데이터 조사결과 4종 어류에 대한 급성독성치만 보고되어 있으며, EUSES시스템에 의하면 어류에서의 최저 PNEC 값(예상 무작용농도)은 0.01mg/l이고 표면수에서의 PEC값(예상 환경농도)은 지역수준에서 최악의 경우 9.1$\times$$10^{-5}$mg/l이다. 지역수준에서 표면수에 대한 아세트아닐리드의 RCR(위해성지수)은 9.1$\times$$10^{-3}$으로 추정되어 어류에 대한 안전성은 충분하다. 그러나 국지 수준에서의 RCR은 물과 침적물에서 각각 1.3과 1.6이므로 제조공장 주변에서는 생태독성 위험이 존재할 것으로 추정된다. 아세트아닐리드의 환경위해성 평가를 보다 정확하게 하기 위해서는 물벼룩과 조류에 대한 급성독성 자료가 보완되어야 할 것이며, 따라서 이에 대한 실험이 진행되어야 할 것으로 사료된다.

• 한국식품영양과학회지
• /
• 제21권3호
• /
• pp.231-240
• /
• 1992

식이속의 단백질농도가 피리딘계 제초제인 gramoxone의 독성발현에 어떤 영향을 미치는가를 알기 위해 Wistar계 흰쥐 수놈 36마리 (6~7주령)를 6개의 실험사료군으로 나누어 2주간 사육하며 그 미치는 영향을 조사하였다. 체중증가 상황은 각단백-gramoxone군들의 경우 각 정상단백군에 비해 저조하였으며 저단백-gramoxone군에서 제일 심하였고 고단백-gramoxone군에서는 유의한 차가 없었다. 간의 지질함량변화는 각단백-gramoxone군들의 경우, 고단백-gramoxone군을 제외하고 각 단백군에 비해 증가하는 경향을 나타내었으며 특히 저단백-gramoxone군에서 가장 심하였다. 간장내 TBA가는 정상단백군, 저단백군, 고단백군 및 고단백-gramoxone군 사이에는 유의차가 없었으나 정상단백-gramoxone군과 저단백-gramoxone군의 경우 전자의 실험군들에 비해 매우 높았다. 정상단백군 및 고단백군의 간에서는 유의한 형태적인 변화가 없었으나 저단백군과 각단백-gramoxone군들에서는 정도의 차이는 이었으나 간조직의 변화가 나타났으며 간세포 지방변화 및 Kupffer 세포의 숫적인 증가가 관찰되었다. 특히 간세포 지방변화는 저단백-gramoxone군에서 심하였고 고단백-gramoxone군에서는 현저하지않았다. 간세포의 glycogen함량은 각단백-gramoxone군들에서 타군들에 비해 증가하는 경향을 보였으며 저단백-gramoxone군에서 제일 심하였다. 제일심하였다.

• BMB Reports
• /
• 제45권3호
• /
• pp.165-170
• /
• 2012

We report here that an ethanol extract of Tetracera scandens, a Vietnamese medicinal plant, has anti-HIV activity and possesses strong inhibitory activity against HIV-1 reverse transcriptase (RTase). Using a MT-4 cell-based assay, we found that the T. scandens extract inhibited effectively HIV virus replication with an $IC_{50}$ value in the range of 2.0-2.5 ${\mu}g$/ml while the cellular toxicity value (CC50) was more than 40-50 ${\mu}g$/ml concentration, thus yielding a minimum specificity index of 20-fold. Moreover, the anti-HIV efficacy of the T. scandens extract was determined to be due, in part, to its potent inhibitory activity against HIV-1 RTase activity in vitro. The inhibitory activity against the RTase was further confirmed by probing viral cDNA production, an intermediate of viral reverse transcription, in virus-infected cells using quantitative DNA-PCR analysis. Thus, these results suggest that T. scandens can be a useful source for the isolation and development of new anti-HIV-1 inhibitor(s).

• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 1997년도 추계학술대회
• /
• pp.35-39
• /
• 1997

Recent development of human genetics and techniques of gene transfer and expression have opened the way for investigating novel approaches based on the genetic modification of cells to treat both inherited and acquired diseases. This approach is referred to as gene therapy. Over the past few years, gene therapy has moved from the laboratory to phase I clinical trials. Although the clinical performance of gene transfer experiments is still in an early phase of development, the NIH of Health Recombinant DNA Advisory Comittee (RAC) has approved more than 150 protocols that involve gene transfer or putative gene therapy procedures in clinical settings. Many sectors of society in United States have participated in the design and formulation of these clinical trials through local Institutional Review Boards, the National Institutes of Health (NIH) RAC, the Chemotherapy Evaluation Program of the National Cancer institute, and the FDA. Currently, clinical trials involving gene modification are under way at many medical centers throughout the United Slates. The goals of these trials are as follows. (1) The design should be directed to short-term achievable goals. (2) Each clinical trial is best considered as an intermediate step in a multistep process. (3) The design should identify evaluable proximate endpoints for toxicity and for efficacy, (4) The potential benefits and possible risks for patients participating in these trial should be defined.